Should I Buy BNTC? BNTC 2026 Analysis

Should You Buy Benitec Biopharma Inc (BNTC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

12.410

1 Day change

-1.43%

52 Week Range

17.150

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

["Not a good buy right now for an impatient buyer: price is sitting right on the pivot (~12.36) with nearby resistance at 12.95\u201313.32 and statistically negative near-term bias (-1.7% next day; -3.84% next month).", "Momentum is improving (MACD histogram positive and expanding), but the setup is not strong enough without a clear breakout above 12.95; risk/reward is not compelling at this exact pre-market level (~12.35).", "Intellectia signals do NOT provide a strong \u201cact-now\u201d edge today (no AI Stock Picker and no SwingMax entry), so there\u2019s no proprietary confirmation to buy aggressively this morning."]

Technical Analysis

["Trend/Momentum: MACD histogram 0.0703 > 0 and expanding \u2192 bullish momentum building, but still early.", "RSI (6): 56.9 (neutral) \u2192 not overbought, but also not showing strong upside pressure.", "Moving averages: converging \u2192 consolidation/indecision rather than a clear uptrend.", "Key levels: Pivot 12.357 (price ~12.35 is essentially on it). Resistance: R1 12.953 then R2 13.321. Support: S1 11.761 then S2 11.393.", "Pattern-based forward odds: 70% chance of -1.7% next day and -3.84% next month \u2192 short-term edge skews slightly bearish despite improving MACD."]

Options Data

Bearish

Technical Summary

Sell

Buy

Positive Catalysts

["Hedge funds are buying: reported buying amount up ~599.83% over the last quarter (supportive flow).", "Technical momentum improving: positive and expanding MACD can precede a push into the 12.95\u201313.32 resistance zone if buying continues.", "Street stance remains positive: H.C. Wainwright maintains a Buy rating."]

Neutral/Negative Catalysts

citing completed equity financing \u2192 dilution/financing overhang is a negative narrative driver.", "Statistical analog signals skew down over 1-day/1-month horizons (increases odds of chop or fade from current levels).", "Options liquidity is very thin \u2192 any \u201cbullish\u201d options tilt is not strongly confirmed by volume."]

Financial Performance

["Latest quarter: 2026/Q1.", "Revenue: 0 (0.00% YoY) \u2192 still pre-revenue/no commercial traction reflected in reported top line.", "Net income: -$8.965M, improved 77.21% YoY (loss narrowed).", "EPS: -0.22, down 54.17% YoY (worse per-share outcome, consistent with dilution/financing effects).", "Overall: operating loss appears improved in absolute terms, but per-share results deteriorated; growth profile remains dependent on pipeline progress rather than revenue."]

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

["Most recent: 2025-11-24 H.C. Wainwright maintained Buy, but lowered price target to $32 from $35 due to completed equity financing.", "Wall Street pros: maintained Buy suggests continued belief in longer-term upside (pipeline optionality).", "Wall Street cons: target cut tied to financing highlights dilution risk and near-term pressure on per-share value."]

3 Analyst Rating

Wall Street analysts forecast BNTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTC is 27 USD with a low forecast of 22 USD and a high forecast of 32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 12.590

Low

Averages

High

Current: 12.590

Low

Averages

High

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$35 -> $32

AI Analysis

2025-11-24

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$35 -> $32

AI Analysis

2025-11-24

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Benitec Biopharma to $32 from $35 and keeps a Buy rating on the shares. The firm cites the completed equity financing for the target cut.

H.C. Wainwright

Buy

maintain

$28 -> $35

2025-11-04

Reason

H.C. Wainwright

Price Target

$28 -> $35

2025-11-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Benitec Biopharma to $35 from $28 and keeps a Buy rating on the shares. The company reported "highly positive" interim data reported from the first six patients to receive BB-301, the analyst tells investors in a research note. The firm says all six patients in the ongoing Phase 1b/2a trial met the formal statistical criteria for positive response in the proprietary oculopharyngeal muscular dystrophy responder analysis. H.C. Wainwright increased BB-301's probability of approval to 45% from 40%.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BNTC

Unlock Now

BNTC Should I Buy

BNTC Should I Buy

Should You Buy Benitec Biopharma Inc (BNTC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch